Evolution of pregnancy planning in hyperprolactinemia
https://doi.org/10.14341/omet13144
Abstract
Hyperprolactinemia has multiple etiologies and is the most common endocrine manifestation of pathology of the hypothalamic-pituitary axis. Hyperprolactinemic hypogonadism is of great scientific interest due to the prevalence of endocrine pathology in the reproductive period and its effect on metabolic processes. Hyperprolactinemia is one of the serious obstacles to the implementation of reproductive function in both women and men. The article discusses current issues of diagnosis and management tactics for patients with hyperprolactinemia of various etiologies within the framework of preconception preparation.
About the Authors
L. K. Dzeranova
Endocrinology Research Centre
Russian Federation
Russian Federation
Larisa K. Dzeranova, MD, PhD
Moscow
S. Yu. Vorotnikova
Endocrinology Research Centre
Russian Federation
Russian Federation
Svetlana Y. Vorotnikova, MD, PhD
Moscow
E. A. Pigarova
Endocrinology Research Centre
Competing Interests:
Competing Interests:
Ekaterina A. Pigarova, MD, PhD
Moscow
References
1. Grattan DR, Jasoni CL, Liu X. et al. Prolactin regulation of gonadotropin-releasing hormone neurons to suppress luteinizing hormone secretion in mice. Endocrinology. 2007;148(9):4344-51. doi: https://doi.org/10.1210/en.2007-0403
2. Brown RS, Piet R, Herbison AE. et al. Differential actions of prolactin on electrical activity and intracellular signal transduction in hypothalamic neurons. Endocrinology. 2012;153(5):2375-84. doi: https://doi.org/10.1210/en.2011-2005
3. Kokay IC, Petersen SL, Grattan DR. Identification of prolactin-sensitive GABA and kisspeptin neurons in regions of the rat hypothalamus involved in the control of fertility. Endocrinology. 2011;152(2):526-35. doi: https://doi.org/10.1210/en.2010-0668
4. Sonigo C, Bouilly J, Carré N. et al. Hyperprolactinemia-induced ovarian acyclicity is reversed by kisspeptin administration. J Clin Invest. 2012;122(10):3791-5. doi: https://doi.org/10.1172/JCI63937
5. Millar RP, Sonigo C, Anderson RA. et al. Hypothalamic-Pituitary-Ovarian Axis Reactivation by Kisspeptin-10 in Hyperprolactinemic Women With Chronic Amenorrhea. J Endocr Soc. 2017;1(11):1362-1371. doi: https://doi.org/10.1210/js.2017-00328
6. Donato J Jr, Frazão R. Interactions between prolactin and kisspeptin to control reproduction. Arch Endocrinol Metab. 2016;60(6):587-595. doi: https://doi.org/10.1590/2359-3997000000230
7. Vlahos NP, Bugg EM, Shamblott MJ. et al. Prolactin receptor gene expression and immunolocalization of the prolactin receptor in human luteinized granulosa cells. Mol Hum Reprod. 2001;7(11):1033-8. doi: https://doi.org/10.1093/molehr/7.11.1033
8. Репродуктивная эндокринология Йена и Джаффе. Физиология, патофизиология, клиника, диагностика и лечение / Джером Ф. Штраус III, Роберт Л. Барбьери, Антонио Р. Гарджуло. — 8-е изд. — Москва : ООО «Издательство «Медицинское информационное агентство», 2022. — 1200 + XVI с. : ил.
9. Андреева Е.Н. Гиперпролактинемия у женщин репродуктивного возраста: что должен помнить врач / Е.Н. Андреева, Е.В. Шереметьева, О.Р. Григорян // Акушерство и гинекология. — 2021. — Т. 9. — С. 204-210
10. Castilla A, García C, Cruz-Soto M. et al. Prolactin in ovarian follicular fluid stimulates endothelial cell proliferation. J Vasc Res. 2010;47(1):45-53. doi: https://doi.org/10.1159/000231720
11. Auriemma RS, Del Vecchio G, Scairati R. et al. The Interplay Between Prolactin and Reproductive System: Focus on Uterine Pathophysiology. Front Endocrinol (Lausanne). 2020;11:594370. doi: https://doi.org/10.3389/fendo.2020.594370
12. Levina VV, Nolen B, Su Y. et al. Biological significance of prolactin in gynecologic cancers. Cancer Res. 2009;69(12):5226-33. doi: https://doi.org/10.1158/0008-5472.CAN-08-4652
13. Alvarez-Payares JC, Bello-Simanca JD, De La Peña-Arrieta EJ. et al. Common Pitfalls in the Interpretation of Endocrine Tests. Front Endocrinol (Lausanne). 2021;12:727628. doi: https://doi.org/10.3389/fendo.2021.727628
14. Koniares K, Benadiva C, Engmann L. et al. Macroprolactinemia: a mini-review and update on clinical practice. F S Rep. 2023;4(3):245-250. doi: https://doi.org/10.1016/j.xfre.2023.05.005
15. Shimatsu A, Hattori N. Macroprolactinemia: Diagnostic, clinical, and pathogenic significance. Clin Dev Immunol. 2012;2012:167132. doi: https://doi.org/10.1155/2012/167132
16. Thirunavakkarasu K, Dutta P, Sridhar S. et al. Macroprolactinemia in hyperprolactinemic infertile women. Endocrine. 2013;4:750–5. doi: https://doi.org/10.1007/s12020-013-9925-y
17. Vilar L, Fleseriu M, Bronstein MD. Challenges and pitfalls in the diagnosis of macroprolactinemia. Arq Bras Endocrinol Metabol. 2014;58:9–22. doi: https://doi.org/10.1590/0004-2730000003002
18. Yang W, Guo Z, Zhou Y. et al. Optimization of a screening method for macroprolactinemia. J Chromatogr B. 2021;1175:122723. doi: https://doi.org/10.1016/j.jchromb.2021.122723
19. Thirunavakkarasu K, Dutta P, Sridhar S. et al. Macroprolactinemia in hyperprolactinemic infertile women. Endocrine. 2013;4:750–5. doi: https://doi.org/10.1007/s12020-013-9925-y
20. Hayashida SAY, Marcondes JAM, Soares JM. et al. Evaluation of macroprolactinemia in 259 women under investigation for polycystic ovary syndrome. Clin Endocrinol 2014;80:616–8. doi: https://doi.org/10.1111/cen.12266
21. Kalsi AK, Halder A, Jain M. et al. Prevalence and reproductive manifestations of macroprolactinemia. Endocrine. 2019;63(2):332-340. doi: https://doi.org/10.1007/s12020-018-1770-6
22. Hu Y, Ni J, Zhang B, Cheng W, Zhang H, Ye H, Ji L, Lu B, Guan M. Establishment of reference intervals of monomeric prolactin to identify macroprolactinemia in Chinese patients with increased total prolactin. BMC Endocr Disord. 2021 Oct 7;21(1):197. doi: https://10.1186/s12902-021-00861-z.
23. Hattori N, Ishihara T, Saiki Y, Shimatsu A. Macroprolactinaemia in patients with hyperprolactinaemia: composition of macroprolactin and stability during long-term follow-up. Clin Endocrinol. 2010;73:792–7. doi: https://doi.org/10.1111/j.1365-2265.2010.03880.x
24. Wallace IR, Satti N, Courtney CH. et al. Ten-year clinical follow-up of a cohort of 51 patients with macroprolactinemia establishes it as a benign variant. J Clin Endocrinol Metab. 2010;95: 3268–71. doi: https://doi.org/10.1210/jc.2010-0114
25. Nishiyama N, Hattori N, Aisaka K. et al. Macroprolactin in mothers and their babies: what is its origin? Clin Chem Lab Med. 2024. doi: https://doi.org/10.1515/cclm-2024-0235
26. Petersenn S, Fleseriu M, Casanueva FF. et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol. 2023;19(12):722-740. doi: https://doi.org/10.1038/s41574-023-00886-5
27. Melmed S, Casanueva FF, Hoffman AR. et al. Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-88. doi: https://doi.org/10.1210/jc.2010-1692
28. Coopmans EC, Korbonits M. Molecular genetic testing in the management of pituitary disease. Clin Endocrinol (Oxf). 2022;97(4):424-435. doi: https://doi.org/10.1111/cen.14706
29. Tarasova TS, Pigarova EA, Dzeranova LK, Tiulpakov AN, Dedov II. Metabolic changes in patients with familial pituitary adenomas associated with mutations in the AIP gene. Obesity and metabolism. 2017;14(1):48-51. (In Russ.). doi: https://doi.org/10.14341/omet2017148-51.
30. de Laat JM, Dekkers OM, Pieterman CR, et al. Long‐term natural course of pituitary tumors in patients with MEN1: results from the DutchMEN1 study group (DMSG). J Clin Endocrinol Metab. 2015;100:3288‐3296. doi: https://doi.org/10.1210/JC.2015-2015
31. Chahal HS, Chapple JP, Frohman LA. et al. Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA). Trends Endocrinol Metab. 2010;21(7):419-27. doi: https://doi.org/10.1016/j.tem.2010.02.007
32. Lima AD, Alves VR, Rocha AR, Martinhago AC, et al. Preimplantation genetic diagnosis for a patient with multiple endocrine neoplasia type 1: case report. JBRA Assist Reprod. 2018;22(1):67-70. doi: https://doi.org/10.5935/1518-0557.20180010
33. Buskila D, Berezin M, Gur H. et al. Autoantibody profile in the sera of women with hyperprolactinemia. J Autoimmun. 1995;8(3):415-24. doi: https://doi.org/10.1006/jaut.1995.0033
34. Кривонос М.И., Зайнулина М.С., Сельков С.А. Антифосфолипидный синдром и ранние репродуктивные потери // Акушерство, гинекология и репродукция. — 2016. — Т. 10. — №4. — С. 114-122
35. Praprotnik S, Agmon-Levin N, Porat-Katz BS, et al. Prolactin’s role in the pathogenesis of the antiphospholipid syndrome. Lupus. 2010;19(13):1515-9. doi: https://doi.org/10.1177/0961203310373781
36. Wallaschofski H, Lohmann T, Hild E, et al. Enhanced platelet activation by prolactin in patients with ischemic stroke. Thromb Haemost. 2006;96(1):38-44. doi: https://doi.org/10.1160/TH05-09-0634
37. Sherer Y, Blank M, Shoenfeld Y. Immunomodulation of experimental antiphospholipid syndrome. Scand J Rheumatol Suppl. 1998;107:48-52. doi: https://doi.org/10.1080/03009742.1998.11720761
38. Raverot V, Perrin P, Chanson P, et al. Prolactin immunoassay: does the high-dose hook effect still exist? Pituitary. 2022;25(4):653-657. doi: https://doi.org/10.1007/s11102-022-01246-8
39. Saei Ghare Naz M, Rostami Dovom M, Ramezani Tehrani F. The Menstrual Disturbances in Endocrine Disorders: A Narrative Review. Int J Endocrinol Metab. 2020;18(4):e106694. doi: https://doi.org/10.5812/ijem.106694/
40. Molitch ME. Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma. Eur J Endocrinol. 2015;172(5):R205-13. doi: https://doi.org/10.1530/EJE-14-0848
41. Прегравидарная подготовка. Клинический протокол Междисциплинарной ассоциации специалистов репродуктивной медицины (МАРС). Версия 3.1 / [Коллектив авторов]. —М.: Редакция журнала StatusPraesens, 2024. — 124 с.
42. Luger A, Broersen LHA, Biermasz NR, et al. ESE Clinical Practice Guideline on functioning and nonfunctioning pituitary adenomas in pregnancy. Eur J Endocrinol. 2021;185(3):G1-G33. doi: https://doi.org/10.1530/EJE-21-0462
43. Giraldi EA, Ioachimescu AG. The Role of Dopamine Agonists in Pituitary Adenomas. Endocrinol Metab Clin North Am. 2020;49(3):453-474. doi: https://doi.org/10.1016/j.ecl.2020.05.006
44. Huang HY, Lin SJ, Zhao WG, Wu ZB. Cabergoline versus bromocriptine for the treatment of giant prolactinomas: A quantitative and systematic review. Metab Brain Dis. 2018;33(3):969-976. doi: https://doi.org/10.1007/s11011-018-0217-3
45. Huang W, Molitch ME. Pituitary Tumors in Pregnancy. Endocrinol Metab Clin North Am. 2019;48(3):569-581. doi: https://doi.org/10.1016/j.ecl.2019.05.004
46. Hurault-Delarue C, Montastruc JL, Beau AB. et al. Pregnancy outcome in women exposed to dopamine agonists during pregnancy: a pharmacoepidemiology study in EFEMERIS database. Arch Gynecol Obstet. 2014;290:263–70
47. Sant’ Anna BG, Musolino NRC, Gadelha MR. et al. A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas. Pituitary. 2020;23(2):120-128. doi: https://doi.org/10.1007/s11102-019-01008-z
48. Glezer A, Bronstein MD. Prolactinomas in pregnancy: considerations before conception and during pregnancy. Pituitary. 2020;23(1):65-69. doi: https://doi.org/10.1007/s11102-019-01010-5
49. Huang W, Molitch ME. Pituitary Tumors in Pregnancy. Endocrinol Metab Clin North Am. 2019;48(3):569-581. doi: https://doi.org/10.1016/j.ecl.2019.05.004
50. Zamanipoor Najafabadi AH, Zandbergen IM, de Vries F, Broersen LHA, et al. Surgery as a Viable Alternative First-Line Treatment for Prolactinoma Patients. A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2020;105(3):e32–41. doi: https://doi.org/10.1210/clinem/dgz144
51. Primeau V, Raftopoulos C, Maiter D. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients. Eur J Endocrinol. 2012;166(5):779-86. doi: https://doi.org/10.1530/EJE-11-1000
52. Buchfelder M, Zhao Y, Schlaffer SM. Surgery for Prolactinomas to Date. Neuroendocrinology. 2019;109(1):77-81. doi: https://doi.org/10.1159/000497331
53. Magro E, Graillon T, Lassave J. et el. Complications Related to the Endoscopic Endonasal Transsphenoidal Approach for Nonfunctioning Pituitary Macroadenomas in 300 Consecutive Patients. World Neurosurg. 2016;89:442-53. doi: https://doi.org/10.1016/j.wneu.2016.02.059
54. Kamel A, Halim AA, Shehata M. et al. Changes in serum prolactin level during intracytoplasmic sperm injection, and efect on clinical pregnancy rate: a prospective observational study. BMC Pregnancy Childbirth. 2018;18:141. doi: https://doi.org/10.1186/s12884-018-1783-4
55. Herman T, Csehely S, Orosz M, et al. Impact of Endocrine Disorders on IVF Outcomes: Results from a Large, Single-Centre, Prospective Study. Reprod Sci. 2023;30(6):1878-1890. doi: https://doi.org/10.1007/s43032-022-01137-0
56. Duan Y, Liu X, Hou W, et al. No impact of treated hyperprolactinemia on cumulative live birth rate and perinatal outcomes in in vitro fertilization-embryo transfer. J Obstet Gynaecol Res. 2019;45:1236–1244
Review
For citations:
Dzeranova L.K., Vorotnikova S.Yu., Pigarova E.A. Evolution of pregnancy planning in hyperprolactinemia. Obesity and metabolism. 2024;21(2):188-194. (In Russ.) https://doi.org/10.14341/omet13144
Views:
1182
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
